This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Wednesday's Health Winners & Losers

Health care stocks were up slightly Wednesday following successful drug studies, announced stock offerings and mixed earnings.

Advanced Life Sciences Holdings (ADLS) announced that its respiratory antibiotic, Cethromycin, was shown to be effective in preventing inhalation anthrax infection in a 30-day study involving 30 primates. Shares rose 27 cents, or 7.9%, to $3.67.

Positive study results also sent Nabi Biopharmaceuticals (NABI) soaring 90 cents, or 17%, to $6.03. The company said a significant number of patients in its phase IIb study for NicVax, a vaccine to treat nicotine addiction, met the primary endpoint of eight weeks of continuous abstinence. Nabi is also set to release first-quarter financial results by end-of-day Wednesday.

Planned stock offerings also moved the market Wednesday. Immunomedics (IMMU) announced it will sell just over 4.8 million shares of common stock to institutional investors for about $24 million, or $4.95 a share. The stock closed at $5.35 Tuesday. The offering is set to close on or around May 7. Shares were up 4 cents, or 0.8%, to $5.39.

Array BioPharma's (ARRY) offer to sell 7 million shares for $13 a share did not have the same impact on investors. The company's stock price fell 53 cents, or 3.9%, to $13. The Array BioPharma offering is also expected to close on or around May 7.

A narrowed quarter-over-quarter loss helped make Pozen (POZN) a winner Wednesday. The pain reduction drug developer reported a net loss of $2.1 million, or 7 cents a share for the first quarter ended March 31, compared to a net loss of $6.4 million, or 22 cents a share for the same quarter last year. The results were good enough to beat the Thomson Financial consensus of a loss of 9 cents a share. Shares hiked 80 cents, or 5.5%, to $15.30.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,943.81 +28.74 0.17%
S&P 500 1,967.57 +2.89 0.15%
NASDAQ 4,415.49 +19.2860 0.44%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs